Stanford University School of Medicine, Stanford, CA 94305, USA.
J Neurooncol. 2012 Feb;106(3):627-35. doi: 10.1007/s11060-011-0702-6. Epub 2011 Sep 1.
Survival outcomes and patterns of care for brain tumor patients in the USA Veterans population have not been previously published and the extent of variation in outcomes between Veterans and the rest of the USA is currently unknown. The Veterans healthcare administration (VA) provides comprehensive care to Veterans and their families and maintains the Veterans affairs central cancer registry (VACCR). This was a retrospective review of microscopically-confirmed, supratentorial glioblastoma multiforme in male Veterans actively followed by the VACCR; survival was analyzed and compared to a national cohort from the surveillance, epidemiology and end results program. We analyzed 1,219 Veterans with glioblastomas diagnosed between 1997 and 2006. Median survival was 6.5 months and 1, 2, and 5 years survival rates were 26.8, 5.4, and 0.5%, respectively. Patients receiving all three treatment modalities (surgical resection, radiotherapy, and chemotherapy) did best; these findings remained true among patients aged 70 and older such that these patients had an overall survival similar to those age <70. A comparable national cohort had longer median survival (9.0 months) and greater 1, 2, and 5 years survival rates (37.8, 12.8, and 4.1%) than the VA cohort. Survival and patterns of care are presented for the first time for Veterans with glioblastoma multiforme. In conclusion, we found that more aggressive therapy was associated with better survival, even among elderly Veterans and whether compared overall or by age group, VA patients showed decreased survival relative to a national cohort. We believe this potential disparity warrants further investigation.
在美国退伍军人人群中,脑肿瘤患者的生存结果和治疗模式尚属首次报道,退伍军人与美国其他人群之间的结果差异程度目前尚不清楚。退伍军人医疗管理局(VA)为退伍军人及其家属提供全面的医疗服务,并维护退伍军人事务中央癌症登记处(VACCR)。这是一项对 VACCR 积极随访的显微镜确诊的男性退伍军人幕上多形性胶质母细胞瘤的回顾性研究;对生存情况进行了分析,并与监测、流行病学和最终结果计划中的全国队列进行了比较。我们分析了 1219 名在 1997 年至 2006 年间被诊断患有胶质母细胞瘤的退伍军人。中位生存期为 6.5 个月,1、2 和 5 年生存率分别为 26.8%、5.4%和 0.5%。接受所有三种治疗方式(手术切除、放疗和化疗)的患者效果最好;在 70 岁及以上的患者中,这些发现仍然成立,因此这些患者的总体生存率与 70 岁以下的患者相似。一个类似的全国队列的中位生存期(9.0 个月)更长,1、2 和 5 年生存率(37.8%、12.8%和 4.1%)更高,与 VA 队列相比。首次为患有多形性胶质母细胞瘤的退伍军人提供了生存和治疗模式。总之,我们发现更积极的治疗与更好的生存相关,即使在老年退伍军人中也是如此,无论总体比较还是按年龄组比较,VA 患者的生存率均低于全国队列。我们认为这种潜在的差异值得进一步调查。